United States:
Cellular Pharmacodynamics Of A Novel Pyrrolo [3, 2-d] Pyrimidine Inhibitor Targeting Mitochondrial And Cytosolic One-Carbon Metabolism
08 May 2020
Kramer Levin Naftalis & Frankel LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Intellectual Property scientific advisor Khushbu Shah
co-authored an article titled "Cellular Pharmacodynamics of a
Novel Pyrrolo [3, 2-d] Pyrimidine Inhibitor Targeting Mitochondrial
and Cytosolic One-Carbon Metabolism" which was published in
Molecular Pharmacology on Jan. 1,
2020.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.
